Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association

Circulation

Volumn 134, Issue 21, 2016, Pages e468-e495

  Wiggins, Barbara S ^a   Saseen, Joseph J ^a   Page, Robert L ^a   Reed, Brent N ^a   Sneed, Kevin ^a   Kostis, John B ^a   Lanfear, David ^a   Virani, Salim ^a   Morris, Pamela B ^a  

^a NONE

Author keywords

AHA Scientific Statements; anti arrhythmic agents; anticoagulants; calcium channel blockers; cardiovascular disease; drug related side effects and adverse reactions; fenofibrate fenofibric acid derivatives; gemfibrozil; hydroxymethylglutaryl CoA reductase inhibitors; immunosuppressive agents

Indexed keywords

AMIODARONE; AMLODIPINE; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CONIVAPTAN; CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; DILTIAZEM; DRONEDARONE; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; IVABRADINE; MULTIDRUG RESISTANCE PROTEIN; NICOTINIC ACID; RANOLAZINE; RAPAMYCIN; SACUBITRIL; TACROLIMUS; TICAGRELOR; VALSARTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VERAPAMIL; WARFARIN;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; PRIORITY JOURNAL; CLINICAL DECISION MAKING; COMORBIDITY; CONSENSUS; DRUG INTERACTION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; MEDICAL SOCIETY; POLYPHARMACY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; CLINICAL DECISION-MAKING; COMORBIDITY; CONSENSUS; DRUG INTERACTIONS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POLYPHARMACY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84991502977     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000456     Document Type: Article

References (189)

1. Tatro DS, ed. Drug Interaction Facts. St. Louis, MO: J.B. Lippincott Co; 1992
2. Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf. 2005;28:371-378.
3. Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ. 1999;161:1266-1267.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009. doi: 10.1056/ NEJM199610033351401.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention and Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357. doi: 10.1056/NEJM199811053391902.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22. doi: 10.1016/S0140-6736(02)09327-3.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
9. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158. doi: 10.1016/ S0140-6736(03)12948-0.
10. Stone N, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in Circulation. 2014;129[suppl 2]:S46-S48 and Circulation. 2015;132:e396]. Circulation. 2014;129(suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a.
11. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360:1155-1162. doi: 10.1016/S0140-6736(02)11203-7.
12. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221. doi: 10.1056/NEJMra032424.
13. Bullman J, Nicholls A, Van Landingham K, Fleck R, Vuong A, Miller J, Alexander S, Messenheimer J. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia. 2011;52:1351-1358. doi: 10.1111/j.1528-1167.2011.03118.x.
14. Dingemanse J, Schaarschmidt D, van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42:293-301. doi: 10.2165/00003088-200342030-00004.
15. Bogman K, Peyer AK, Török M, Küsters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol. 2001;132:1183-1192. doi: 10.1038/sj.bjp.0703920.
16. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343-370. doi: 10.2165/00003088-200241050-00003.
17. Hochman JH, Pudvah N, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res. 2004;21:1686-1691.
18. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001;18:800-806.
19. Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMGCoA reductase. J Pharm Pharmacol. 2005;57:1305-1311. doi: 10.1211/jpp.57.10.0009.
20. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs [published correction appears in J Am Coll Cardiol. 2014;63:2176]. J Am Coll Cardiol. 2013;61:2495-2502. doi: 10.1016/j.jacc.2013. 02.058.
21. US Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors, and inducers. http:// www.fda.gov/drugs/developmentapprovalprocess/development resources/druginteractionslabeling/ucm093664.htm. Accessed August 7, 2014.
22. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693-705. doi: 10.1111/j.1476-5381.2009.00430.x.
23. Hua WJ, Hua WX, Fang HJ. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther. 2012;30:e234-e241. doi: 10.1111/j.1755-5922.2011.00290.x.
24. Atorvastatin (Lipitor) [package insert]. New York, NY: Pfizer; 2013.
25. Fluvastatin sodium (Lescol, Lescol XL) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2012.
26. Lovastatin (Mevacor) [package insert]. Whitehouse Station, NJ: Merck &Co, Inc; 2014.
27. Pravastatin (Pravachol) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2013.
28. Rosuvastatin (Crestor) [package insert]. Wilmington, DE: Aztra-Zeneca Pharmaceuticals; 2013.
29. Simvastatin (Zocor) [package insert]. Whitehouse Station, NJ: Merck &Co, Inc; 2014.
30. Pitavastatin (Livalo) [package insert]. Montgomery, AL: Kowa Pharmaceuticals; 2013.
31. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol. 2001;57:357-364.
32. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2003;21:199-215.
33. Rodriques AD. Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. Drug Metab Lett.2007;1:31-35.
34. Farnier M. Safety review of combination drugs for hyperlipidemia. Expert Opin Drug Saf. 2011;10:363-371. doi: 10.1517/14740338.2011.540237.
35. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311:228-236. doi: 10.1124/jpet.104.068536.
36. Paragh G, Balogh Z, Romics L. Antilipemic therapy and rhabdomyolysis [in Hungarian]. Orv Hetil. 2003;144:515-520.
37. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs. JAMA. 2004;292:2585-2590. doi: 10.1001/ jama.292.21.2585.
38. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMGCoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417-426. doi: 10.1002/ pds.977.
39. Layne RD, Sehbai AS, Stark LJ. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother. 2004;38:232-234. doi: 10.1345/aph.1D282.
40. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12:565-569.
41. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120-122. doi: 10.1016/j.amjcard.2004.08.076.
42. Amend KL, Landon J, Thyagarajan V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011;45:1230-1239. doi: 10.1345/aph.1Q110.
43. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418. doi: 10.1056/NEJM199908053410604.
44. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245. doi: 10.1056/NEJM198711123172001.
45. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA. 1990;264:71-75.
46. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(suppl): 3C-18C.
47. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. Am J Cardiol. 2004;94:935-938. doi: 10.1016/ j.amjcard.2004.06.033.
48. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol. 2006;97:27C-31C. doi: 10.1016/ j.amjcard.2005.12.007.
49. Lopid (gemfibrozil) tablets [package insert]. New York, NY: Parke-Davis; revised 2010.
50. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006;34:191-197. doi: 10.1124/dmd.105.007633.
51. Okerholm RA, Keeley FJ, Peterson FE, Glazko AJ. The metabolism of gemfibrozil. Proc R Soc Med. 1976;69(suppl 2):11-14.
52. Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther. 2012;92:584-598. doi: 10.1038/clpt.2012.163.
53. Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007;35:1315-1324. doi: 10.1124/ dmd.107.015230.
54. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68:122-129. doi: 10.1067/mcp.2000.108507.
55. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001;69:340-345.
56. Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol. 2011;51:378-388. doi: 10.1177/0091270010366446.
57. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78:154-167. doi: 10.1016/j.clpt.2005.04.007.
58. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 2003;73:538-544. doi: 10.1016/S0009-9236(03)00052-3.
59. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455-463.
60. Bergman E, Matsson EM, Hedeland M, Bondesson U, Knutson L, Lennernäs H. Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. J Clin Pharmacol. 2010;50:1039-1049. doi: 10.1177/0091270009357432.
61. Mathew P, Cuddy T, Tracewell WG, Salazar D. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther. 2004;75:33.
62. Noé J, Portmann R, Brun ME, Funk C. Substrate-dependent drugdrug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007;35:1308-1314. doi: 10.1124/dmd.106.012930.
63. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol. 1995;76:80A-83A.
64. Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy: a nationwide register study. PLoS One. 2013;8:e69545. doi: 10.1371/journal.pone.0069545.
65. Abbvie Inc. TRICOR (fenofibrate) tablets [package insert]. http:// www.rxabbvie.com/pdf/tricorpi.pdf. Accessed June 7, 2014.
66. Abbvie Inc. TRILIPIX (fenofibric acid) capsules [package insert]. http:// www.rxabbvie.com/pdf/trilipix-pi.pdf. Accessed June 7, 2014.
67. Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease: current concepts and dilemmas [published correction appears in J Am Coll Cardiol. 2004;44:2283]. J Am Coll Cardiol. 2004;44:1343-1353. doi: 10.1016/j. jacc.2004.06.058.
68. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280-1287.
69. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, Wallin BA. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000;40:316-323.
70. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25:459-471.
71. Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, Wan K, Chira TO, Pradhan RS. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009;49:63-71. doi: 10.1177/0091270008325671.
72. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD Study Investigators. Effects of longterm fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial [published correction appears in Lancet. 2006;368:1420]. Lancet. 2005;366:1849-1861. doi: 10.1016/S0140-6736(05)67667-2.
73. Accord Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574. doi: 10.1056/ NEJMoa1001282.
74. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [published correction appears in N Engl J Med. 2012;367:189]. N Engl J Med. 2011;365:2255-2267. doi: 10.1056/NEJMoa1107579.
75. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-1291. doi:10.1093/eurheartj/eht55.
76. Triggle DJ. Calcium channel antagonists: clinical uses-past, present and future. Biochem Pharmacol. 2007;74:1-9. doi: 10.1016/j.bcp.2007.01.016.
77. Kaski JC, Aldama G, Cosín-Sales J. Cardiac syndrome X: diagnosis, pathogenesis and management. Am J Cardiovasc Drugs. 2004;4:179-194.
78. Romero M, Sánchez I, Pujol MD. New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships. Curr Med Chem Cardiovasc Hematol Agents. 2003;1:113-141.
79. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf. 2008;31:587-596.
80. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-The-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008;47:463-474. doi: 10.2165/00003088-200847070-00003.
81. Rifkin SI. Multiple drug interactions in a renal transplant patient leading to simvastatin-induced rhabdomyolysis: a case report. Medscape J Med. 2008;10:264.
82. You JH, Chan WK, Chung PF, Hu M, Tomlinson B. Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. J Clin Pharmacol. 2010;50:1151-1158. doi: 10.1177/0091270009358082.
83. Hu M, Mak VW, Tomlinson B. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition. J Clin Pharm Ther. 2011;36:419-425. doi: 10.1111/ j.1365-2710.2010.01184.x.
84. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther. 2000;67:267-274. doi: 10.1067/mcp.2000.104609.
85. Azie MD, Brater DC, Becker PA,Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64:369-377.
86. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann Pharmacother. 2002;36:1546-1549.
87. Choi DH, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet. 2009;34:163-168.
88. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. JAMA. 2002;288:2981-2997.
89. Amlodipine [package insert]. New York, NY: Pfizer Labs; 2011.
90. Diltiazem [package insert]. Macquarie Park, NSW: Sanofi-Aventis, Australia Pty Ltd; 2014.
91. Verapamil [package insert]. New York, NY: Pfizer Labs; 2011.
92. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol. 2005;8:95-97.
93. Pfizer Inc. CORDARONE (amiodarone HCL) tablets. http:// labeling.pfizer.com/showlabeling.aspx?id=93. Accessed June 9, 2014.
94. Sanofi-Aventis US LLC. MULTAQ (dronedarone) tablets. http:// www.multaq.com/docs/consumer-pdf/pi.aspx. Accessed June 22, 2014.
95. Wratchford P, Ponte CD. High-dose simvastatin and rhabdomyolysis. Am J Health Syst Pharm. 2003;60:698-700.
96. de Denus S, Spinler SA. Amiodarone's role in simvastatin-associated rhabdomyolysis. Am J Health Syst Pharm. 2003;60:1791; author reply 1791-1792.
97. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother. 2004;38:978-981. doi: 10.1345/ aph.1D498.
98. Saliba WR, Elias M. Myopathy from the combination of simvastatin and amiodarone. Eur J Intern Med. 2006;17:148. doi: 10.1016/j.ejim.2005.09.018.
99. Ricaurte B, Guirguis A, Taylor HC, Zabriskie D. Simvastatinamiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother. 2006;40:753-757. doi: 10.1345/aph.1G462.
100. Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin Belg. 2011;66:134-136. doi: 10.2143/ ACB.66.2.20625533.
101. Merz T, Fuller SH. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone. Am J Health Syst Pharm. 2007;64:1818-1821. doi: 10.2146/ajhp060305.
102. Chouhan UM, Chakrabarti S, Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother. 2005;39:1760-1761. doi: 10.1345/aph.1G195.
103. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther. 2007;81:679-684. doi: 10.1038/ sj.clpt.6100098.
104. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376:1658-1669. doi: 10.1016/ S0140-6736(10)60310-8.
105. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711-1718.
106. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT: Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators [published correction appears in Lancet. 1997;349:1776]. Lancet. 1997;349:675-682.
107. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493-498.
108. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT: European Myocardial Infarct Amiodarone Trial Investigators [published corrections appear in Lancet. 1997;349:1180 and Lancet. 1997;349:1776]. Lancet. 1997;349:667-674.
109. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias: the Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-1583. doi: 10.1056/NEJM199711273372202.
110. Borders-Hemphill V. Concurrent use of statins and amiodarone. Consult Pharm. 2009;24:372-379.
111. Karimi S, Hough A, Beckey C, Parra D. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center. J Manag Care Pharm. 2010;16:472-481. doi: 10.18553/jmcp.2010.16.7.472.
112. Zhelyazkova-Savova M, Gancheva S, Sirakova V. Potential statin-drug interactions: prevalence and clinical significance. Springerplus. 2014;3:168. doi: 10.1186/2193-1801-3-168.
113. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007;41:599-605. doi: 10.1345/aph.1H524.
114. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation [published correction appears in N Engl J Med. 2009;360:2487]. N Engl J Med. 2009;360:668-678. doi: 10.1056/NEJMoa0803778.
115. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999. doi: 10.1056/NEJMoa054686.
116. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605. doi: 10.1111/j.1540-8167.2010.01764.x.
117. Digoxin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009. http://www.accessdata.fda.gov/drugsatfda- docs/label/2010/009330s025lbl.pdf. Accessed August 28, 2016.
118. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40: 91-98.
119. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45:469-491. doi: 10.2165/00003088-200645050-00003.
120. Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005;45:422-433. doi: 10.1177/0091270004273992.
121. Hylton AC, Ezekiel TO. Rhabdomyolysis in a patient receiving ranolazine and simvastatin. Am J Health Syst Pharm. 2010;67:1829-1831. doi: 10.2146/ajhp090299.
122. Correa D, Landau M. Ranolazine-induced myopathy in a patient on chronic statin therapy. J Clin Neuromuscul Dis. 2013;14:114-116. doi: 10.1097/CND.0b013e31828525a5.
123. Ginanneschi F, Volpi N, Giannini F, Rocchi R, Donati D, Aglianò M, Lorenzoni P, Rossi A. Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal. J Neurol Sci. 2014;336:284-287. doi: 10.1016/j.jns.2013.10.040.
124. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E; MERLIN-TIMI 36 Trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297:1775-1783. doi: 10.1001/ jama.297.16.1775.
125. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, Chaitman BR. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61:2038-2045. doi: 10.1016/j.jacc.2013.02.011.
126. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316. doi: 10.1001/jama.291.3.309.
127. Ranolazine [package insert]. Foster City, CA; Gilead Sciences, Inc. January 2016.
128. Kellick KA, Bottorff M, Toth PP, National Lipid Association's Safety Task Force. A clinician's guide to statin drug-drug interactions. J Clin Lipidol. 2014;8(suppl):S30-S46. doi: 10.1016/j. jacl.2014.02.010.
129. Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond). 2012;73:106-107.
130. Hickmott H, Wynne H, Kamali F. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost. 2003;89:949-950. doi: 10.1267/ THRO03050949.
131. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol. 2006;62:291-296. doi: 10.1007/s00228-006-0104-4.
132. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:86-90.
133. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost. 2006;4:1422-1424. doi: 10.1111/j.1538-7836.2006.01974.x.
134. Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9 3 allele. Pharmacogenomics. 2012;13:757-762. doi: 10.2217/pgs.12.40.
135. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother. 2007;41:1292-1295. doi: 10.1345/aph.1K167.
136. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction. Ann Pharmacother. 1997;31:790.
137. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30:1399-1402.
138. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy. 2004;24:285-290.
139. Ahmad S. Lovastatin: warfarin interaction. Arch Intern Med. 1990;150:2407.
140. Barry M. Rosuvastatin-warfarin drug interaction. Lancet. 2004;363:328. doi: 10.1016/S0140-6736(03)15396-2.
141. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol. 2005;45:927-934. doi: 10.1177/0091270005278224.
142. Yu CY, Campbell SE, Zhu B, Knadler MP, Small DS, Sponseller CA, Hunt TL, Morgan RE. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steadystate warfarin. Curr Med Res Opin. 2012;28:187-194. doi: 10.1185/03007995.2011.648264.
143. Jindal D, Tandon M, Sharma S, Pillai KK. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol. 2005;61:621-625. doi: 10.1007/s00228-005-0986-6.
144. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol. 1997;37:1062-1064.
145. AstraZeneca. Ticagrelor [package insert]. http://www1.astrazenecaus. com/pi/brilinta.pdf. Accessed May 10, 2014.
146. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477-487. doi: 10.1007/s00228-012-1369-4.
147. Dinicolantonio JJ, Serebruany VL. Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology. 2013;124:105-107. doi: 10.1159/000346151.
148. US Food and Drug Administration. Drug approval package. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 022433Orig1s000TOC.cfm. Accessed October 23, 2014.
149. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators,Freij A, Thorsén M;. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.
150. Astellas Pharma US, Inc. Conivaptan [package insert]. http:// www.astellas.us/docs/vaprisol.pdf. Accessed May 10, 2014.
151. Otsuka. Tolvaptan [package insert]. http://www.otsuka-us.com/ products/Documents/Samsca.PI.pdf. Accessed August 28, 2016.
152. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, Fedson S, Fisher P, Gonzales-Stawinski G, Martinelli L, McGiffin D, Smith J, Taylor D, Meiser B, Webber S, Baran D, Carboni M, Dengler T, Feldman D, Frigerio M, Kfoury A, Kim D, Kobashigawa J, Shullo M, Stehlik J, Teuteberg J, Uber P, Zuckermann A, Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G, Delgado D, Eisen H, Goldberg L, Hosenpud J, Johnson M, Keogh A, Lewis C, O'Connell J, Rogers J, Ross H, Russell S, Vanhaecke J; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914-956. doi: 10.1016/j.healun.2010.05.034.
153. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N,Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627. doi: 10.1056/NEJM199509073331003.
154. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K, Steinbeck G, Seidel D, Reichart B. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93-97.
155. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, Seidel D, Reichart B. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96:1398-1402.
156. Lindenfeld J, Page RL 2nd, Zolty R, Shakar SF, Levi M, Lowes B, Wolfel EE, Miller GG. Drug therapy in the heart transplant recipient, part III: common medical problems. Circulation. 2005;111:113-117. doi: 10.1161/01.CIR.0000151609.60618.3C.
157. Zakliczynski M, Boguslawska J, Wojniak E, Zakliczynska H, Ciesla D, Nozynski J, Szygula-Jurkiewicz B, Zeglen S, Zembala M. In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: a cross-sectional study. Transplant Proc. 2011;43:3071-3073. doi: 10.1016/j. transproceed.2011.08.052.
158. Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient, part IV: drug-drug interactions. Circulation. 2005;111:230-239. doi: 10.1161/01. CIR.0000151805.86933.35.
159. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporine: an update. Clin Pharmacokinet. 1996;30:141-179.
160. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404-430. doi: 10.2165/00003088-199529060-00003.
161. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80:565-581. doi: 10.1016/j.clpt.2006.09.003.
162. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
163. Altoprev oral extended-release tablets, lovastatin oral extendedrelease tablets. http://www.accessdata.fda.gov/drugsatfda- docs/label/2012/021316s026lbl.pdf. Accessed August 28, 2016.
164. Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant. 2005;5:2236-2243. doi: 10.1111/ j.1600-6143.2005.01005.x.
165. Aliabadi AZ, Mahr S, Dunkler D, Grömmer M, Zimpfer D, Wolner E, Grimm M, Zuckermann AO. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation. 2008;86:1771-1776. doi: 10.1097/TP.0b013e3181910eb2.
166. Basic-Jukic N, Kes P, Bubic-Filipi L, Vranjican Z. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient. Nephrol Dial Transplant. 2010;25:2036; author reply 2036-2037. doi: 10.1093/ ndt/gfq157.
167. Dopazo C, Bilbao I, Lázaro JL, Sapisochin G, Caralt M, Blanco L, Castells L, Charco R. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant Proc. 2009;41: 1021-1024. doi: 10.1016/j.transproceed.2009.02.019.
168. Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002;42: 222-228.
169. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404-410. doi: 10.1016/j. jacc.2012.10.027.
170. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30:799-802. doi: 10.1002/mus.20135.
171. Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40:1466-1469. doi: 10.1345/ aph.1H064.
172. Sahin G, Korkmaz C, Yalcin AU. Which statin should be used together with colchicine? Clinical experience in three patients with nephrotic syndrome due to AA type amyloidosis. Rheumatol Int. 2008;28:289-291. doi: 10.1007/s00296-007-0435-1.
173. Montiel V, Huberlant V, Vincent MF, Bonbled F, Hantson P. Multiple organ failure after an overdose of less than 0.4 mg/ kg of colchicine: role of coingestants and drugs during intensive care management. Clin Toxicol (Phila). 2010;48:845-848. doi: 10.3109/15563650.2010.509101.
174. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother. 2005;39:1368-1369. doi: 10.1345/aph.1E653.
175. Sarullo FM, Americo L, Di Franco A, Di Pasquale P. Rhabdomyolysis induced by co-administration of fluvastatin and colchicine. Monaldi Arch Chest Dis. 2010;74:147-149. doi: 10.4081/monaldi.2010.264.
176. Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy: a case report. Neurotoxicology. 2006;27:1126-1127. doi: 10.1016/j.neuro.2006.09.003.
177. Alayli G, Cengiz K, Cantürk F, Durmuş D, Akyol Y, Menekşe EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39:1358-1361. doi: 10.1345/aph.1E593.
178. Bouquié R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol. 2011;17:28-30. doi: 10.1097/ RHU.0b013e3182056042.
179. Hsu WC, Chen WH, Chang MT, Chiu HC. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol. 2002;25:266-268.
180. Francis L, Bonilla E, Soforo E, Neupane H, Nakhla H, Fuller C, Perl A. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol. 2008;27:129-131. doi: 10.1007/ s10067-007-0696-9.
181. Justiniano M, Dold S, Espinoza LR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13:266-268. doi: 10.1097/RHU.0b013e318156d977.
182. Oh DH, Chan SQ, Wilson AM. Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin. Med J Aust. 2012;197:332-333.
183. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study [published correction appears in Lancet. 2010;376:1988]. Lancet. 2010;376:875-885. doi: 10.1016/ S0140-6736(10)61198-1.
184. Ivabradine, Corlanor [package insert]. Thousand Oaks, CA: Amgen; 2015.
185. European Medicines Agent. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000597/WC500043590. pdf. Accessed April 21, 2016.
186. Sacubratril/Valsartan, Entresto [package insert]. East Hanover, NJ: Novartis; 2015.
187. European Medicines Agency. Assessment report: Entresto. 2015. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Public-assessment-report/human/004062/ WC500197538.pdf. Accessed April 21, 2016.
188. US Food and Drug Administration. Center for Drug Evaluation and Research: application number 207620Orig1s000: clinical pharmacology and biopharmaceutics review(s). http://www. accessdata.fda.gov/drugsatfda-docs/nda/2015/207620Orig1 s000ClinPharmR.pdf. Accessed April 21, 2016.
189. http://www.hiv-druginteractions.org/. Accessed August 28, 2016.